Myelodysplastic syndrome with t(9;11)(p22;q23) after treatment for B-cell acute lymphoblastic leukemia without epipodophyllotoxins.
Secondary myelodysplastic syndrome (MDS) with t(9;11)(p22;q23) developed in a child after intensive treatment for B-cell acute lymphoblastic leukemia diagnosed 12 months earlier. His chemotherapy had consisted mainly of cyclophosphamide and methotrexate, but no epipodophyllotoxins. The combination of MDS, the cytogenetic anomaly involving bands at 11q23 and no previous exposure to epipodophyllotoxins represents a unique case of therapy-related leukemia.
Kubota
M
M
Department of Pediatrics, Kyoto University, Japan.
Hoshino
Y
Y
Doi
H
H
Ueno
H
H
Nishida
Y
Y
Hirota
H
H
Akiyama
Y
Y
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D016026:Bone Marrow Transplantation; D002051:Burkitt Lymphoma / Q000150:complications* / Q000188:drug therapy; D002648:Child; D002869:Chromosome Aberrations / Q000235:genetics*; D002880:Chromosomes, Human, Pair 11; D002899:Chromosomes, Human, Pair 9; D006801:Humans; D007621:Karyotyping; D008297:Male; D009190:Myelodysplastic Syndromes / Q000139:chemically induced* / Q000235:genetics / Q000628:therapy; D011034:Podophyllotoxin; D012074:Remission Induction
D011034:Podophyllotoxin